

To Evaluate Clinical Efficacy of Intravenous Midazolam Alone and Along with Propofol for Sedation in Patient Management During Interventional Endoscopic Procedures

1. Muhammad Salman Maqbool 2. Muhammad Umer Draz 3. Arshad Saleem Shahani
4. Muhammad Iqbal

1. Asstt. Prof. of Anaesthesiology & Intensive Care, Rawal Institute of Health Sciences, Islamabad
2. MO, Medical Unit-II, Benazir Bhutto Hospital, Rawalpindi 3. Senior Registrar of Anaesthesia,
Holy Family Hospital, Rawalpindi 4. Anaesthetist, Rawal Institute of Health Sciences, Islamabad

ABSTRACT

Objective: Ample patient's sedation is a requisite for most interventional endoscopic procedures. A study was conducted to evaluate clinical efficacy of sedation using short acting anesthetic propofol with midazolam than midazolam alone in patient management during diagnostic and therapeutic endoscopic procedures.

Study Design: Prospective observational study

Place and Duration of Study: This study was conducted at radiology suite and endoscopy unit, by Department of Medicine, Gastroenterology & Hepatology Division, Holy Family Hospital, Rawalpindi, from 23-12-2009 to 21-6-2010

Materials and Method: A total of ninety two patients undergoing endoscopic procedures randomly received either midazolam (n = 47, group A) or propofol plus midazolam (n= 45, group B) sedation. Patient vital signs were noted as well as recovery scores, patient's tolerance of the procedure (visual analog scale). Modified Richmond Agitation-Sedation Score (RASS Scale) was used to assess degree of sedation. The immediate and intermediate recovery was assessed using Steward's recovery score and Post Anesthesia Discharge score (PADS) respectively.

Results: Chi-square test value was 79.23 with P value of 0.001 and is significant, while Correlation co-efficient (r) value was 0.800 and the correlation was significant at 0.02 level.

Conclusion: Propofol along with midazolam is safe for interventional endoscopic procedures under adequate patient monitoring and is more effective than sedation with midazolam alone as post procedural recovery is concerned while sedation efficacy being similar.

Key Words: Midazolam, Propofol, Endoscopic Procedures

INTRODUCTION

Gastrointestinal endoscopic procedures can be unpleasant minimally painful and prolonged e.g., Endoscopic Retrograde Cholangiopancreatography or drainage procedures. It requires relative patient's immobility to prevent degradation of fluoroscopic image. Therefore, sedation should on principle be offered to patient.¹ This challenges the anesthesiologist of providing adequate sedation, analgesia, while ensuring rapid recovery. A variety of agents have been used for sedation.^{2,3}

Midazolam short-acting benzodiazepine is commonly used for endoscopy⁴, with potency 1.5–3.5 greater than diazepam.⁵ It reaches maximum effect after 3–4 minutes, the duration of effect being 15 - 80 minutes⁶ depending on cofactors such as obesity, age, and systemic disease. Its short initial distribution half-life of 3-10 minutes is responsible for awakening.⁷ The drug produces reliable amnesia, and anti-anxiety effects. Midazolam is preferable to diazepam due to rapid recovery and nonpainful induction.⁸ In few cases

where benzodiazepines fail to provide adequate patient comfort opioids are added.⁹

Propofol (2,6-diisopropylphenol) is a sedative, the mechanism of action involves facilitation of inhibitory neurotransmitter γ -aminobutyric acid. Propofol is lipophilic, onset of action is rapid and awakening from single dose is due to short initial distribution half life.⁷ Favorable results have been reported for propofol sedation during endoscopy but is expensive and may lead to respiratory arrest when used in higher doses.¹⁰

Recent data suggest synergism of pharmacological effects between midazolam and propofol as combination will reduce dosage needed,¹¹ expense may be less and also reduces side-effects while retaining the individual advantages.¹² In view of above stated facts, a study was conducted with aim of observing clinical effects of sedative agents i.e. midazolam alone and along with propofol administered by anesthesiologist for interventional endoscopy on hemodynamic, respiration, operator easiness and comfort, amnesia, recovery time and scores, patient acceptability and procedure tolerance (visual analogue scale), along with complications.

MATERIALS AND METHODS

After approval of hospital ethical committee and acquiring informed consent, this prospective observational study, was conducted at radiology suite and endoscopy unit, by Department of Medicine, Gastroenterology & Hepatology Division, Holy Family Hospital, Rawalpindi, from 23-12-2009 to 21-6-2010. All patients had pre-procedure evaluation done. A total of ninety two patients were studied with age group from 18 to 85 years and belonging to American Society of Anesthesiologist(ASA) physical status class 1-3 and medically optimized class-4. Excluded were patients aged less than 18 years, difficult airway, bronchial asthma, heart disease, uncompensated hepatic/ renal disease, pregnant and lactating mother and emergency situation cases (e.g. upper gastrointestinal bleeding). All patients received Inj. Drotraverine 20mg and Inj. Nalbuphine 1-2mg intramuscularly. Patients randomly received either midazolam alone (n=47, group A, loading dose of 2.5-3.5 mg intravenously and repeat doses of 0.5-1mg) or propofol plus midazolam (n=45, group B, loading dose of propofol 40-60 mg intravenously and bolus dose of 20 mg and a initial midazolam dose of 2.5-3.5 mg) intravenously. The patients were placed comfortably on radiology table in lateral position. Electrocardiography, pulse oxymeter, and blood pressure were noted serially. Oxygen at 2-4L/min via nose cannula was given. The time between injection of sedative and moment of final withdrawal of endoscope was total procedure duration. The modified RASS Scale¹³ was used to assess level of sedation during procedure. At end of procedure, Stewart's recovery score¹⁴ was noted to assess immediate recovery. The PADS system^{15,16} was employed to assess intermediate recovery before shifting patients to either respective wards/home. Before discharge patient were asked to state experience of procedure on visual analogue scale of 0 - 10, i.e., poor to good experience.

Data was analyzed by SPSS version 18. Chi-square test was used to compare Stewart recovery score and grades of PADS score attained for association, while Spearman's Rank correlation was also used to check interdependence between them. The P-value of <0.05 will be statistically significant.

RESULTS

In group A, mean bolus dose of 1 ± 0.5 mg midazolam was used plus additional mean dose of 6.12 mg during procedure with a standard deviation of 3.65, in group B initial loading propofol dose of 20 mg used in a single patient, plus mean additional dose of 113mg with a standard deviation of 66.16 along with initial dose $2.5 \text{ mg} \pm 0.5$ of midazolam and intra-procedure midazolam dose of 2.76mg with a standard deviation of 0.85 was used. The lowering of systolic blood pressure

< 90 mmHg observed in two out of 47 patients i.e. 4.25% of cases in group A and while in group B noted in one out of forty five patients i.e. 2.2% of cases respectively. The temporary oxygen desaturation (< 85 %) in group A and B occurred in four patients i.e, 8.5% and in two patients i.e, 4.4% of cases respectively. The mean saturation in group A and B being 97.23% and 97.45% respectively.

The mean recovery time in group A being 10 ± 5 min and mean procedure times being 79.11 min whereas in group B same figures were 3 ± 2 min and 88.6 min respectively. The minimal recommended Stewart recovery score and PADS was attained by all cases in study. The sedation efficacy was rated similar in both groups by endoscopist. Visual Analogue score being stated as good to excellent in both groups. The modified RASS Scale score in group A and B being 1 and 2 in 95% of cases and in 5% cases was scale 3 sedation score. The demographic data of both groups is shown in table-1.

Table No.1: Demographic Data

	Group A	Group B
Age[years (mean/standard deviation)]	50.80/13.07	49.08/14.19
Sex (male/females)(n/%)	18/29 - 38.8/61.7	19/26 - 42.2/57.8
ASA-class I (n/%)	16/34	17/37.8
ASA-class II (n/%)	12/25.5	14/31.1
ASA-class III (n/%)	19/40.4	13/28.9
ASA-class IV (n/%)	0/	1/ 2.2

In the study drugs used for premedication in group A were Inj. Drotraverine which was used in 42 cases i.e, 95.4% of cases and in seventeen cases i.e, 38.6% was used during procedure, while in 4.5% i.e, two cases it was not used. Inj. Drotraverine median dose was 40mg, with a standard deviation of 22.33 before and during procedure, whereas Inj. Nalbuphine was used in fortyone i.e, 91.1% of cases in dose of 2mg and Inj. gravinate was used as pre-medication in fortythree i.e, 97.7 % of cases in a dose of 25mg. Meanwhile in group B, Inj. Drotraverine was used in 44 cases i.e, 97.7% of cases and in fortyone cases i.e, 38.6% was used during procedure, while in 2.1% i.e, one case it was not used. Inj. Drotraverine median dose was 30mg, with a standard deviation of 26.20 before and during procedure, whereas Inj. Nalbuphine was used in fortyone i.e, 89.1% of cases in a dose of 2.5 mg as pre-medication and in similar dose used in a single case during procedure whereas in four i.e, 8.7% of cases it was not used, while Inj. gravinate was used as pre-medication in fortythree i.e. 91.5 % of cases in a dose 25 mg whereas in four i.e, 8.5% of cases it was not used. In study, Chi-square test value was 79.23 with P-value of 0.001 and significant. Spearman's Rank

correlation test value (r) came out to be 0.800 and was significant at 0.02 level.

DISCUSSION

Safe proceedings of interventional endoscopy demand meticulous follow-up of standard protocols. The examination is usually of shorter duration has low complication and mortality rate.^{17,18} In the United States and the United Kingdom, 88% endoscopic examinations are done under sedation^{2,3} a recent survey shows sedation frequency of 87% for endoscopy in Germany.¹⁹ Every patient has right to endoscopic examination as stress-free as possible. It therefore appears ethically unjustifiable to withhold sedation.¹ In our study a single case was postponed due to non co-operative patient and request was to repeat under supervision of anesthesiologist as it was the only case in which sedation was given by medical personal. The higher rate of patient acceptance of endoscopic examinations owing to sedation is demonstrated in other studies,²⁰ but this increases cost and is responsible for about 50% of complications.²¹ However, a few national study of European countries have investigated the rate of using conscious sedation for routine diagnostic upper gastrointestinal endoscopy in their country.²² The decision of using premedication is influenced by national and cultural differences among countries, as well as patients wishes and endoscopists attitude.²³

The drug dose was tailored to type of intervention and patient's ASA grade in our study. Since most complications in sedated gastroscopy are of cardiopulmonary nature, monitoring is important to prevent them,²⁴ mild hemodynamic alterations during our study were immediately managed. Endoscopist satisfaction was noted with presence of anesthesiologist in our study.

In complex interventions moderate sedation is needed to ensure that examination is done safely.²⁵ In study by Jung and colleagues²⁶ significantly higher endoscopist satisfaction was noted with propofol. The intermittent bolus administration of propofol is currently the best documented form of administration in endoscopy.^{27,28,29} It was used in our study. There is evidence supporting use of propofol with benzodiazepines (eg, midazolam) and/or opiates (eg, fentanyl), a study done in this regard by Van Natta³⁰ and colleagues employing combination therapy, depicted smaller dose requirement of propofol to obtain moderate rather than deep sedation.

Midazolam is given as a bolus of 30–80 µg/kg body weight for gastroscopy,³¹ subsequently, lower-dose boli are given for desired sedation depth,³² the use of lower doses of midazolam is recommended for patients older than 60 years.³³ In our study similar protocol was followed.

In risk factor analysis by Wehrmann and Riphaut³⁴ a total of 135 adverse events (1.4%) were documented. Assisted ventilation was necessary in forty patients (0.4%); nine patients required endotracheal intubation (0.09%); twenty eight needed further monitoring on the intensive care unit (0.3%); and four patients died, three potentially due to sedation-related side effects (mortality, 0.03%). In our study surgical exploration was advised in one case immediately on assessment, mild bleeding was noted in four cases which settled with adrenaline local application, in eight cases fresh frozen plasma had to be given and in one case inj. vitamin K was administered.

Post-interventional monitoring is necessary to detect any sequelae of sedation. The duration of this phase depends on the expected risk.³⁵ Close monitoring of the patient by qualified personnel should be continued, patients can be released when their vital signs are stable and are fully oriented.³⁶ In our study patients were kept in recovery area with full resuscitation facility before shifting to medical intensive care or respective wards depending upon recovery score attained. However, in our study a single case of anaphylactic reaction/shivering leading to respiratory distress had to be managed by mask ventilation and later intubated briefly (lasting 8 minutes) in the patient receiving propofol/ midazolam sedation in recovery area.

The minimum discharge criteria as stated in the guidelines³⁷ was implemented in our study. Prophylactic oxygen administration via a nasal tube can significantly reduce the frequency of hypoxemic events during endoscopy.³⁸

In the study done by Ladas and colleagues⁴ at least two sedatives were reported to be in use in every country. In about 1/3rd of the countries or representative endoscopy units, more than one category of personnel was responsible for administering sedation. Endoscopists are required to obtain training in the safe administration of propofol before using it in clinical practice, for this purpose "The American Society for Gastrointestinal Endoscopy" has published recommendations regarding the learning objectives required for formal training in propofol administration.³⁹ In study done by Byrne and colleagues,⁴⁰ they recommended that endoscopists seeking to use propofol in their practice should undergo: 1) certification in 'advanced cardiac life support'; and 2) a preceptorship or formal course of instruction with an individual (such as an anesthesiologist) who is familiar with propofol use.

CONCLUSION

Propofol along with midazolam is safe for interventional endoscopic procedures under adequate patient monitoring and is more effective than sedation with midazolam alone as post procedural recovery is concerned while sedation efficacy being similar. Sedation also required availability of adequate

monitoring and resuscitation facilities in the endoscopy unit.

REFERENCES

1. Probert CS, Jayanthi V, Quinn J, Mayberry JF. Information requirements and sedation preferences of patients undergoing endoscopy of the upper gastrointestinal tract. *Endoscopy* 1991;23: 218–219.
2. Keeffe EB, O'Connor KW. 1989 A/S/G/E survey of endoscopic sedation and monitoring practices. *Gastrointest Endosc* 1990; 36: 13–18.
3. Daneshmend TK, Bell GD, Logan RF. Sedation for upper gastrointestinal endoscopy: results of a nationwide survey. *Gut* 1991; 32: 12–15.
4. Ladas SD, Aabakken L, Rey JF, Nowak A, Zakaria S, Adamonis KN, Amrani N, et al. Use of sedation for routine diagnostic upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy Survey of National Endoscopy Society Members. *Digestion* 2006;74:69–77.
5. Zakko SF, Seifert HA, Gross JB. A comparison of midazolam and diazepam for conscious sedation during colonoscopy in a prospective double-blind study. *Gastrointest Endosc* 1999;49: 684–689.
6. Cantor DS, Baldrige ET. Premedication with meperidine and diazepam for upper gastrointestinal endoscopy precludes the need for topical anesthesia. *Gastrointest Endosc* 1986; 32: 339–341.
7. Morgan GE, Mikhail MS, Murray MJ. *Clinical Anesthesiology*. 4th ed. McGraw-Hill Companies Inc; 2005.p.187-203.
8. Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. *Anaesthesiol* 1985; 62:310-24.
9. Diab FH, King PD, Barthel JS, Marshall JB. Efficacy and safety of combined meperidine and midazolam for EGD sedation compared with midazolam alone. *Am J Gastroenterol* 1996; 91(6): 1120-5.
10. Wehrmann T, Kokabpick S, Lembcke B, Caspary WF, Seifert H. Efficacy and safety of intravenous propofol sedation during routine ERCP. a prospective, controlled study. *Gastrointest Endosc* 1999; 49: 677-83.
11. McClune S, McKay AC, Wright PM, Patterson CC, Clarke RS. Synergistic interaction between midazolam and propofol. *Br J Anaesth* 1992; 69(3): 240-5.
12. Short TG, Chui PT. Propofol and midazolam act synergistically in combination. *Br J Anaesth* 1991; 67:539-45.
13. Ely EW, Truman B, Shintani A, Thomason JW, Wheeler AP, Gordon S et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Score (RASS). *JAMA* 2003; 289(22):2983–91.
14. Steward DJ. A simplified scoring system for the post-operative recovery room. *Canad Anaesth Soc J* 1975; 22(1):111-3.
15. Marshall S, Chung F. Assessment of 'home readiness': discharge criteria and postdischarge complications. *Curr Opin Anaesthesiol* 1997; 10(6): 445-50.
16. Chung F. Are discharge criteria changing? *J Clin Anesth* 1993;5:64-8.
17. American Society for Gastrointestinal Endoscopy: Complication of upper GI endoscopy. *Gastrointest Endosc* 2002; 55: 748–793.
18. Heuss LT, Froehlich F, Beglinger C: Changing patterns of sedation and monitoring practice during endoscopy: results of a nationwide survey in Switzerland. *Endoscopy* 2005;37:161-166.
19. Riphaut A, Rabofski M, Wehrmann T. Endoscopic sedation and monitoring practice in Germany: results from the first nationwide survey 2010; 48(3):392-7.
20. Lazzaroni M, Bianchi, Porro G. Preparation, premedication and surveillance. *Endoscopy* 2005; 37(2):101–9.
21. Bell GD: Preparation, premedication, surveillance. *Endoscopy* 2004; 36: 23–31.
22. Campo R, Brullet E, Junquera F, Puig-Divi V, Vergara M, Calvet X, et al. Sedation in digestive endoscopy. Results of a hospital survey in Catalonia (Spain). *Gastroenterol Hepatol* 2004; 27:503–507.
23. Thompson DG, Lennard-Jones JE, Evans SJ, Cowan RE, Murray RS, Wright JT. Patients appreciate premedication for endoscopy. *Lancet* 1980; 2: 469–470.
24. Iber FL, Sutberry M, Gupta R, Kruss D. Evaluation of complications during and after conscious sedation for endoscopy using pulse oximetry. *Gastrointest Endosc* 1993;39:620–625.
25. Patel S, Vargo JJ, Khandwala F, Lopez R, Trolli P, Dumot JA, Conwell DL, Zuccaro G. Deep sedation occurs frequently during elective endoscopy with meperidine and midazolam. *Am J Gastroenterol*. 2005;100(12):2689-95.
26. Jung M, Hofmann C, Kiesslich R, Brackertz A. Improved sedation in diagnostic and therapeutic ERCP: propofol is an alternative to midazolam. *Endoscopy* 2000; 32: 233–238.
27. Riphaut A, Wehrmann T, Weber B, Arnold J, Beilenhoff U, Bitter H, et al. S3 Guideline: sedation for gastrointestinal endoscopy 2008... *Endoscopy* 2009; 41: 787–815.
28. Rex DK, Overley CA, Walker J. Registered nurse-administered propofol sedation for upper endoscopy and colonoscopy: Why? When? How? *Rev Gastroenterol Disord*. 2003;3:70–80.
29. Chen SC, Rex DK. Review article: Registered nurse-administered propofol sedation for

- endoscopy. *Aliment Pharmacol Ther* 2004;19: 147–55.
30. Van Natta ME, Rex DK. Propofol alone titrated to deep sedation versus propofol in combination with opioids and/or benzodiazepines and titrated to moderate sedation for colonoscopy. *Am J Gastroenterol* 2006;101:2209–17.
31. Carlsson U, Grattidge P. Sedation for upper gastrointestinal endoscopy: a comparative study of propofol and midazolam. *Endoscopy* 1995;27: 240–243.
32. Yano H, Iishi H, Tatsuta M, et al. Oxygen desaturation during sedation for colonoscopy in elderly patients. *Hepatogastroenterology* 1998; 45: 2138–2141.
33. Lee SY, Son HJ, Lee JM, et al. Identification of factors that influence conscious sedation in gastrointestinal endoscopy. *J Korean Med Sci* 2004; 19: 536–540.
34. Wehrmann T, Riphaut A. Sedation with propofol for interventional endoscopic procedures: a risk factor analysis. *Scand J Gastroenterol* 2008;43(3): 368–74.
35. American Society for Gastrointestinal Endoscopy. Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. *Gastrointest Endosc* 2003; 58: 317–322.
36. Stufe 1 Leitlinie Sedierung und Analgesie (Analgesedierung) von Patienten durch Nicht-Anästhesisten. 2008. Available from: http://www.dgai.de/06pdf/13_573-Leitlinie.pdf, <http://intranet/awmf11/001-011.htm>
37. Royal College of Surgeons of England Commission on the Provision of Surgical Services. Report of the working party on guidelines for sedation by non-anesthetists. 1993. www.rcseng.ac.uk/fds/clinical/guidelines-31k
38. Reshef R, Shiller M, Kinberg R, Rennert H, Rennert G, Herskovits M, Loberant N. A prospective study evaluating the usefulness of continuous supplemental oxygen in various endoscopic procedures. *Isr J Med Sci* 1996; 32(9):736–40.
39. American Society for Gastrointestinal Endoscopy. Training guideline for use of propofol in gastrointestinal endoscopy. *Gastrointest Endosc* 2004; 60: 167–172.
40. Byrne MF, Chiba N, Singh H, Sadowski DC. Propofol use for sedation during endoscopy in adults: A Canadian Association of Gastroenterology position statement *Can J Gastroenterol* 2008;22:5.

Address for Corresponding Author:**Dr. Muhammad Salman Maqbool**Address: H.No.573, St.No.69, Sector I-8/3,
Islamabad

Cell: 0345-5117736

e-mail: salman5732000@yahoo.com